Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers.
J Med Virol 2022;
94:3714-3721. [PMID:
35420709 PMCID:
PMC9088645 DOI:
10.1002/jmv.27782]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Revised: 03/30/2022] [Accepted: 04/11/2022] [Indexed: 11/09/2022]
Abstract
Vaccination certainly is the best way to fight against the COVID-19 pandemic. In this study, the seroconversion effectiveness of two vaccines against SARS-CoV-2 was assessed in healthcare workers: virus-inactivated CoronaVac (CV, n=303), and adenovirus-vectored Oxford-AstraZeneca (AZ, n=447). The IgG antibodies anti-spike glycoprotein and anti-nucleocapsid protein were assessed by Enzyme-Linked Immunosorbent Assay (ELISA) at the time before vaccination (T1), before the second dose (T2), and 30 days after the second dose (T3). Of all individuals vaccinated with AZ, 100% (n=447) exhibited seroconversion, compared to 91% (n=276) that were given CV vaccine. Among individuals who did not respond to the CV, only three individuals showed a significant increase in the antibody level four months later the booster dose. A lower seroconversion rate was observed in elders immunized with CV vaccine probably due to the natural immune senescence, or peculiarity of this vaccine. The AZ vaccine induced a higher humoral response; however, more common side effects were also observed. Non-vaccinated convalescent individuals revealed a similar rate of anti-spike IgG to individuals that were given 2 doses of CV vaccine, which suggests that only a one-shot COVID-19 vaccine could produce an effective immune response in convalescents. This article is protected by copyright. All rights reserved.
Collapse